Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab plus FLOT.
|Articles|July 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 7
- Volume 5
- Issue 7
University of Pittsburgh, Abbott Labs to Develop Ras Inhibitors
PITTSBURGH--The University of Pittsburgh, through the researchof investigators Saïd Sebti, PhD, and Andrew Hamilton, PhD,has entered into a research agreement with Abbott Laboratoriesto develop novel cancer drugs that block the activity of the rasoncogene.
Advertisement
PITTSBURGH--The University of Pittsburgh, through the researchof investigators Saïd Sebti, PhD, and Andrew Hamilton, PhD,has entered into a research agreement with Abbott Laboratoriesto develop novel cancer drugs that block the activity of the rasoncogene.
Articles in this issue
over 30 years ago
Princess Diana Helps Raise Over $1 Million for Cancer Researchover 30 years ago
Study Gives Terminal Patients Option: $18,000 or More Treatmentover 30 years ago
Proven: Colorectal Screening Cuts Deaths 50%over 30 years ago
Virtual Colonoscopy Technique Feasible in Detecting Polypsover 30 years ago
Trimetrexate Appears Beneficial in Colorectal Cancerover 30 years ago
FDA Liaison Program Answers Patients' Questions About Trialsover 30 years ago
New Company Joins With RPR To Develop Intrabody Technologyover 30 years ago
More Insurers Covering ABMT, Despite Lack of Efficacy Dataover 30 years ago
CDC Says Teen Smoking Still RisingAdvertisement
Related to this article
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
3
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
4
Which New Service Lines Should a Radiation Oncology Department Launch?
5